Here are the 10-Q quarterly reports from OSR Health Inc WTS (OSRHW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OSRHW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OSRHW filings page.
OSR Health, Inc., a healthcare holding company focused on immunotherapies, biologics and medical devices, reported substantially lower losses but sharply reduced revenue for the quarter and six months ended June 30, 2026. Net sales were $315,669 for the quarter and $799,727 for the first half of 2026, down 72% and 58% from the prior-year periods, largely reflecting a shift at subsidiary RMC from a purchase-and-resale model to a consignment, commission-based arrangement and prior one-time inventory sales.
Gross profit nonetheless improved, with quarterly gross margin rising from about 3% to 27%. Operating loss was $3.0 million for the quarter and $6.7 million year-to-date, both narrower than 2025, aided by lower SG&A and the absence of 2025 business-combination costs. Net loss attributable to OSR Health was $3.8 million for the first half. Total assets were $166.6 million and total liabilities $41.7 million.
Liquidity remains tight: cash and cash equivalents were $1.5 million, with $3.4 million of net cash used in operations in the first half. The company is relying on an $80 million equity line of credit, under which it has raised $3.38 million to date, and a 5% convertible note with a fixed $1.00 conversion price and a potential discounted alternative price if Nasdaq non-compliance is not cured. In June 2026, OSR announced a shareholder loyalty CVR program that may deliver up to 5 additional shares per share if specified price thresholds are met over 12 months. Management confirms ongoing material weaknesses in internal control over financial reporting, particularly around liabilities and accounting staffing, and states that remediation efforts are in progress.